1. Kappen PR, Kakar E, Dirven CMF, et al. Delirium in neurosurgery: a systematic review and meta-analysis. Neurosurg Rev. 2022;45:329−41.

2. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. t.

3. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.

4. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

5. The Cochrane Collaboration. Review Manager (RevMan 8.1.1) [Internet]. London: Cochrane; [cited 2024 Nov 26]. Available from: https://revman.cochrane.org/.

6. Li S, Li R, Li M, et al. Dexmedetomidine administration during brain tumour resection for prevention of postoperative delirium: a randomised trial. Br J Anaesth. 2023;130:e307−16.

7. Chen P-H, Tsuang F-Y, Lee C-T, et al. Neuroprotective effects of intraoperative dexmedetomidine versus saline infusion combined with goal-directed haemodynamic therapy for patients undergoing cranial surgery: a randomised controlled trial. Eur J Anaesthesiol. 2021;38:1262−71.

8. Tang CL, Li J, Zhang ZT, et al. Neuroprotective effect of bispectral index-guided fast-track anesthesia using sevoflurane combined with dexmedetomidine for intracranial aneurysm embolization. Neural Regen Res. 2018;13:280−8.

9. Karakaya D, Cakir-Aktas C, Uzun S, Soylemezoglu F, Mut M. Tailored therapeutic doses of dexmedetomidine in evolving neuroinflammation after traumatic brain injury. Neurocrit Care. 2022;36:802−14.

10. Feng X, Ma W, Zhu J, Jiao W, Wang Y. Dexmedetomidine alleviates early brain injury following traumatic brain injury by inhibiting autophagy and neuroinflammation through the ROS/Nrf2 signaling pathway. Mol Med Rep. 2021;24:661.